Innate Pharma SA Gain Loss On Remeasurement Of Net Defined Benefit Liability Asset
Innate Pharma SA (IPHA) reported Gain Loss On Remeasurement Of Net Defined Benefit Liability Asset of EUR 94.00 thousand for the 12-month period ending 2025-12-31, per its 20-F filed 2026-04-01.
Financial Statements › Income Statement › Other Income
ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset · last filed 2026-04-01
| Period end | Gain Loss On Remeasurement Of Net Defined Benefit Liability Asset 6 month | Gain Loss On Remeasurement Of Net Defined Benefit Liability Asset 12 month |
|---|---|---|
| 2025-12-31 | 94.00K EUR 20-F · filed 2026-04-01 | |
| 2025-06-30 | 13.00K EUR 6-K · filed 2025-09-17 | |
| 2024-12-31 | 36.00K EUR 20-F · filed 2026-04-01 | |
| 2024-06-30 | 116.00K EUR 6-K · filed 2024-09-12 | |
| 2023-12-31 | 394.00K EUR 20-F · filed 2026-04-01 | |
| 2023-06-30 | 101.00K EUR 6-K · filed 2023-09-14 | |
| 2022-12-31 | 790.00K EUR 20-F · filed 2025-04-30 | |
| 2022-06-30 | 471.00K EUR 6-K · filed 2022-09-15 | |
| 2021-12-31 | 584.00K EUR 20-F · filed 2024-04-04 | |
| 2021-06-30 | 566.00K EUR 6-K · filed 2021-09-15 | |
| 2020-12-31 | -200.00K EUR 20-F · filed 2023-04-06 | |
| 2019-12-31 | 622.00K EUR 20-F · filed 2022-04-04 | |
| 2018-12-31 | -599.00K EUR 20-F · filed 2021-04-27 | |
| 2017-12-31 | 196.00K EUR 20-F · filed 2020-04-24 |